Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

Marton König; Hilde Marie Torgauten; The Trung Tran; Trygve Holmøy; John Torgils Vaage; Fridtjof Lund-Johansen; Gro Owren Nygaard

doi:10.1001/jamaneurol.2021.5109

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

JAMA Neurol. 2022 Mar 1;79(3):307-309. doi: 10.1001/jamaneurol.2021.5109.

Authors

Marton König¹, Hilde Marie Torgauten², The Trung Tran³, Trygve Holmøy⁴, John Torgils Vaage³, Fridtjof Lund-Johansen³, Gro Owren Nygaard¹

Affiliations

¹ Department of Neurology, Oslo University Hospital, Oslo, Norway.
² Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
³ Department of Immunology, Oslo University Hospital, Oslo, Norway.
⁴ Department of Neurology, Akershus University Hospital, Oslo, Norway.

Abstract

This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.

MeSH terms

Antibodies, Viral
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
Immunity
Multiple Sclerosis*
SARS-CoV-2
Vaccination / adverse effects

Substances

Antibodies, Viral
COVID-19 Vaccines